

REMARKS

Claims 37, 39, 41-46, 54, 55, 58, 65 and 83-96 are pending. Claims 83-96 are rejected. By virtue of this response, claims 88 and 93 have been cancelled without prejudice and claims 83 and 87 have been amended. Accordingly, claims 37, 39, 41-46, 54, 55, 58, 65, 83-87, 89-92 and 94-96 are currently under consideration.

For the Examiner's convenience, Applicants' remarks are presented in the same order in which they were raised in the Office Action.

Claim Rejections – 35 USC § 112

Claims 83-96 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for: a method for reducing tissue factor (TF) levels to treat a tumor exhibiting TF expression, comprising administering to a human having the tumor a therapeutically effective amount of an anti-TF antibody that comprises six hypervariable regions which comprise sequences of SEQ ID NOS: 5-10 or a chimeric antibody of such anti-TF antibody, does not allegedly provide enablement for administering the antibody to a human having any tumors. The Examiner has stated on page 4 of the Office Action that amending the claim to “administering to a human having the tumors” would obviate the rejection.

For the sole purpose of expediting prosecution, Applicants have amended claim 83 as suggested by the Examiner. Claims 84-86, 89-92, and 94-96 depend from claim 83. Accordingly, Applicants submit that claims 83-86, 89-92, and 94-96 are fully enabled.

In view of the foregoing, Applicants respectfully request withdrawal of this rejection.

Claim Rejections – 35 USC § 112

Claims 87, 88 and 93 are rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the written description requirement.

Without acquiescing to the rejection and for the sole purpose of expediting prosecution, Applicants have amended claim 87 and cancelled claims 88 and 93. Amended claim 87 now refers to antibodies comprising the sequence of SEQ ID NO:2 and SEQ ID NO:4. In view of the foregoing, Applicants respectfully request withdrawal of this rejection.

Allowed Claims

The Examiner has allowed claims 37, 39, 41-46, 54, 55, 58 and 65. Applicants thank the Examiner for allowing these claims.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 146392002520. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 6, 2009

Respectfully submitted,

Electronic signature: /Terri Shieh-Newton/
Terri Shieh-Newton

Registration No.: 47,081
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5777